Prostate Zones & Anatomy
Zonal Anatomy of the Prostate
The prostate is a fibromuscular glandular organ (~20g normal, walnut-sized) lying inferior to the bladder, surrounding the proximal urethra.
70%
Peripheral Zone
Posterior and lateral. Most common site of prostate cancer (70–80%). Palpable on DRE.
25%
Transition Zone
Periurethral. Primary site of BPH. Enlarges with age causing LUTS.
~5%
Central Zone
Surrounds ejaculatory ducts. Rarely site of cancer. Less clinically significant.
Stroma
Fibromuscular Stroma
Anterior capsule. Smooth muscle fibres contribute to urethral tone. Target of alpha-blockers.
Digital Rectal Examination (DRE)
Nursing Awareness
DRE is performed by the physician/advanced practitioner. The nurse prepares the patient, ensures privacy, obtains consent, and assists with positioning. Document findings as reported.
| Finding | Implication |
|---|---|
| Soft, smooth, symmetric | Normal / consistent with BPH |
| Enlarged, soft | BPH — grade I–IV enlargement |
| Hard, irregular, nodular | Concerning for malignancy → refer |
| Fixed, loss of median sulcus | Locally advanced cancer (T3/T4) |
| Tender, boggy | Consider prostatitis |
Key Nursing Point
Hard or irregular findings on DRE require urgent PSA and urology referral regardless of PSA level.
PSA (Prostate Specific Antigen)
| Parameter | Value / Significance |
|---|---|
| Total PSA | <4 ng/mL generally normal; >10 ng/mL high concern |
| PSA Density | PSA ÷ prostate volume; >0.15 concerning |
| PSA Velocity | Rise >0.75 ng/mL/year warrants investigation |
| Free:Total Ratio | <10% — higher cancer risk; >25% — lower risk |
Pre-PSA Nursing Checklist
- No ejaculation 48h prior
- No vigorous exercise 48h prior
- No DRE/TRUS 1 week prior
- No UTI / catheterisation (can falsely elevate)
- Note: BPH, prostatitis, cycling can all raise PSA
Uroflowmetry & Post-Void Residual
| Test | Normal | Abnormal |
|---|---|---|
| Qmax (peak flow) | >15 mL/s | <10 mL/s = obstruction |
| Voided volume | >150 mL (valid test) | <150 mL = unreliable |
| Post-void residual (PVR) | <50 mL | >150 mL = significant |
| PVR 50–150 mL | Borderline — monitor | |
Nursing Role
Instruct patient to void privately into uroflowmetry device with comfortably full bladder. Perform bladder scan for PVR within 5–10 minutes of voiding.
TRUS-Guided Biopsy — Nursing Care
Transrectal Ultrasound-guided prostate biopsy — 12-core systematic ± targeted cores.
Pre-Procedure Preparation
- Review anticoagulants — stop warfarin 5d, NOAC 48h per protocol
- Prophylactic antibiotics as prescribed (quinolone / augmented)
- Rectal enema night before or morning of procedure
- Informed consent — explain discomfort, bleeding risk, sepsis risk
- Confirm allergy status (latex, local anaesthetic)
Post-Procedure Instructions
- Haematuria, haematospermia, rectal bleeding — expected up to 2 weeks
- Report fever >38°C, rigors, inability to void → ED immediately (sepsis)
- Complete full antibiotic course
- Avoid strenuous activity 48h, sexual activity 1 week
IPSS — International Prostate Symptom Score Calculator
IPSS Symptom Score Calculator
Answer all 7 symptom questions (0 = Not at all → 5 = Almost always). The Quality of Life question does not contribute to the IPSS total but guides counselling.
⚠ URGENT: If the patient cannot void at all, has severe suprapubic pain, or is in acute urinary retention — Send to Emergency Department immediately. Do not wait for IPSS scoring.
IPSS Total Score
0
Score Breakdown
Scale: 0 (none) → 35 (severe)
Benign Prostatic Hyperplasia (BPH)
Pathophysiology
- DHT (dihydrotestosterone) mediates stromal and epithelial hyperplasia in the transition zone
- Testosterone → DHT via 5-alpha-reductase type II in prostate stroma
- DHT binds androgen receptors → cell proliferation > apoptosis
- Mechanical obstruction from enlarged gland + dynamic component (smooth muscle tone)
- Prevalence: ~50% of men at age 60; ~90% by age 85
- Not pre-malignant but co-exists with prostate cancer
LUTS Classification
Storage (Irritative) Symptoms
- Urinary frequency (>8 voids/day)
- Urgency — sudden compelling desire to void
- Nocturia — ≥2 voids per night = significant
- Urge incontinence — leakage with urgency
Voiding (Obstructive) Symptoms
- Hesitancy — difficulty initiating
- Poor / weak stream
- Straining to void
- Intermittency — start/stop stream
- Incomplete emptying sensation
- Post-micturition dribble
Medical Management
Drug Therapy
| Drug Class | Example | Mechanism | Key Nursing Points |
|---|---|---|---|
| Alpha-Blocker | Tamsulosin 0.4mg OD Alfuzosin 10mg OD Doxazosin 4–8mg OD |
Block alpha-1 receptors → relax smooth muscle in bladder neck and prostate stroma → improved flow | Postural hypotension — advise rising slowly, especially first dose. Doxazosin: cardiovascular monitoring. Tamsulosin: retrograde ejaculation common. Effect within 1–2 weeks. |
| 5-ARI | Finasteride 5mg OD Dutasteride 0.5mg OD |
Inhibit 5-alpha-reductase → reduce DHT → shrink prostate (20–30% volume reduction) | 6–12 months to full effect. Reduces PSA by ~50% (adjust interpretation). Teratogenicity — women of childbearing age must NOT handle crushed tablets. Sexual side effects: decreased libido, ED, ejaculatory disorder. Do not donate blood while on finasteride. |
| Combination | Tamsulosin + Dutasteride (Duodart) | Dual mechanism: symptom relief + volume reduction | Best for large glands (>40mL) with moderate-severe IPSS. Additive side effects. Continue long-term. |
| Anticholinergic / Beta-3 | Solifenacin, Mirabegron | For storage/overactive bladder component | Caution with anticholinergics if PVR >150mL (risk of retention). Mirabegron safer profile. Monitor blood pressure with mirabegron. |
Acute Urinary Retention (AUR)
Presentation
Sudden inability to void despite urge + full bladder. Severe suprapubic pain and distress. Tender, palpable suprapubic mass. Bladder scan typically >400–500 mL.
1
Immediate IDC insertion — urethral catheter 14–16Fr. Document drained volume. Drain slowly if >800mL (risk of haematuria ex vacuo).
2
Commence alpha-blocker — alfuzosin 10mg OD or tamsulosin 0.4mg for 2–3 days before TWOC.
3
Trial Without Catheter (TWOC) — remove catheter after 24–48h on alpha-blocker. Monitor voiding trial with uroflowmetry and PVR.
4
Failed TWOC → re-catheterise, urology referral for surgical management (TURP / minimally invasive).
Nursing Alert — Haematuria ex vacuo
Decompressing a large retention (>800mL) too rapidly can cause terminal haematuria. Drain 500mL, clamp 10–15 min, then drain remainder.
Chronic Urinary Retention (CUR)
Key Distinction from AUR
CUR is typically painless. Patient does not feel discomfort despite very large residual volumes (500–2000mL). Often discovered incidentally.
- Overflow incontinence — continuous dribbling
- Bilateral hydronephrosis → obstructive renal failure (raised creatinine)
- May present with uraemic symptoms: nausea, lethargy, confusion
- Catheterise urgently; monitor for post-obstructive diuresis
Post-Obstructive Diuresis
Urine output may reach 200–500mL/hour after relieving CUR. Monitor U&E hourly initially, IV replacement if output >200mL/h, strict fluid balance. Risk of hypokalaemia, hyponatraemia, dehydration.
Lifestyle Advice for BPH (All Patients)
- Reduce evening fluids — restrict after 6pm
- Limit caffeine and alcohol (bladder irritants)
- Timed / double voiding technique
- Avoid constipation (pressure on urethra)
- Review medications: diuretics, antihistamines, decongestants
TURP — Transurethral Resection of the Prostate
Pre-Operative Preparation
1
Anticoagulation review: Warfarin stop 5 days (INR <1.5). NOACs: stop 24–48h per drug/renal function. Aspirin: discuss with surgeon (often continue). Clopidogrel: stop 5–7 days.
2
Informed consent documentation: Ensure patient has been counselled on retrograde ejaculation (~90%), temporary incontinence, erectile dysfunction risk (~10%), and need for future procedures.
3
Baseline investigations: U&E, FBC, coagulation, group & screen. Urine C&S — treat UTI before surgery. ECG if >55 years or cardiac history.
4
NBM: 6h solids, 2h clear fluids. IV access. Bowel prep is NOT required for TURP.
5
DVT prophylaxis: TED stockings pre-op, LMWH as per protocol.
TURP Syndrome — Intraoperative Emergency
Mechanism
Absorption of large volume of hypotonic irrigating fluid (glycine 1.5% in monopolar TURP) through open venous sinuses → dilutional hyponatraemia + fluid overload. Risk increases with resection time >60 min.
Clinical Features (Na <125 mmol/L)
- Confusion, agitation, visual disturbance
- Bradycardia, hypertension (raised ICP)
- Nausea and vomiting
- Seizures, coma if severe (Na <115)
Management
- STOP the procedure immediately
- Check serum sodium urgently
- Hypertonic saline (3% NaCl) — guided by Na; correct slowly (<12 mmol/L/24h to avoid osmotic demyelination)
- IV furosemide — promote free water excretion
- Airway protection if GCS dropping
- Bipolar TURP / laser TURP uses normal saline → eliminates glycine toxicity risk
Post-Operative Nursing Care
Continuous Bladder Irrigation (CBI)
Setup
- Normal saline 0.9% only — do not use water or 5% dextrose
- 3-way urethral catheter (18–20Fr) for inflow, drainage, and balloon
- Rate titrated to maintain pale pink/rose urine colour
- Typical starting rate: 100–200 mL/h; increase if heavily blood-stained
- Accurate fluid balance: total output − irrigation in = true urine output
Clot Retention — Recognition & Management
- Signs: drainage slows/stops, suprapubic discomfort, bladder distension, patient distress
- First action: check catheter not kinked/blocked
- Manual irrigation (bladder syringe with 50mL NS) — aspirate and flush to dislodge clot
- If manual washout fails → call urology / change catheter
- Document irrigation volumes in/out
CBI Discontinuation
CBI can usually be discontinued when urine is pale yellow/clear — typically 12–24h post-op for uncomplicated cases. Progress to catheter-free drainage before voiding trial.
Post-Op Monitoring (First 24h)
| Parameter | Frequency | Concerning Value |
|---|---|---|
| Vital signs | 1-hourly × 4h, then 2-hourly | HR >100, SBP <90, T >38.5°C |
| Urine output (net) | Hourly via fluid balance | <0.5 mL/kg/h |
| Haematuria degree | Continuous observation | Bright red, clots, blockage |
| Pain score (VAS) | 2-hourly | Score >6 — escalate |
| Serum sodium | 4h post-op, then per results | <130 mmol/L — review |
| Bladder spasm | Ongoing | Intense spasm — catheter check, analgesia |
Catheter Removal & Voiding Trial
1
Day 1–2 post-op: Deflate balloon and remove catheter when urine is clear/pale and CBI stopped. Morning removal preferred.
2
Voiding trial: Encourage fluid intake 1.5–2L/day. First void should occur within 4–6h. Monitor stream and document volume.
3
Post-void residual: Bladder scan within 10 min of voiding. PVR <100mL = acceptable. PVR >200mL = failed trial → re-catheterise.
4
Discharge advice: Haematuria may recur 7–14 days post-op (scab separation). Increase fluid intake if blood appears. Avoid heavy lifting and straining for 4–6 weeks.
5
Incontinence: Reassure patient that temporary stress/urge incontinence is common post-TURP. Commence pelvic floor exercises. Usually resolves within 6–8 weeks.
Prostate Cancer — Staging & Investigation
TNM Staging
| Stage | Description |
|---|---|
| T1 | Clinically inapparent — not palpable, not visible on imaging. Found incidentally (TURP chip, elevated PSA). |
| T2 | Palpable tumour confined within prostate (T2a: ≤half one lobe; T2b: >half one lobe; T2c: both lobes). |
| T3 | Extra-capsular extension (T3a) or seminal vesicle invasion (T3b). |
| T4 | Invasion of adjacent structures: bladder, rectum, pelvic wall, external sphincter. |
| N1 | Regional lymph node involvement. |
| M1 | Distant metastases (M1a: non-regional nodes; M1b: bone; M1c: other sites). |
Gleason Score & ISUP Grade Groups
| ISUP Grade | Gleason Score | Description |
|---|---|---|
| Grade 1 | Gleason 3+3=6 | Well differentiated. Low risk. |
| Grade 2 | Gleason 3+4=7 | Predominantly well-diff. Favourable intermediate. |
| Grade 3 | Gleason 4+3=7 | Predominantly poorly-diff. Unfavourable intermediate. |
| Grade 4 | Gleason 4+4=8 | Poorly differentiated. High risk. |
| Grade 5 | Gleason 9–10 | Very poorly differentiated. Very high risk. |
Nursing Note
Always document ISUP Grade Group alongside Gleason. Grade group 1 patients may be suitable for active surveillance — reassure about overtreatment risk and surveillance protocol.
Risk Stratification
| Risk Group | Criteria | Primary Management Options |
|---|---|---|
| Low Risk | PSA <10, ISUP 1 (Gleason 6), cT1–T2a | Active surveillance (preferred if life expectancy >10y), watchful waiting, radical prostatectomy or radiotherapy |
| Favourable Intermediate | PSA 10–20 or ISUP 2, cT2b, <50% biopsy cores positive | Active surveillance (selected cases), radical prostatectomy ± pelvic LN dissection, radiotherapy ± short-course ADT |
| Unfavourable Intermediate | ISUP 3 or PSA 10–20 with adverse features | Radical prostatectomy + pelvic LN dissection, radiotherapy + 6 months ADT |
| High Risk | PSA >20, ISUP 4, or cT3a | Radiotherapy + 2–3 years ADT, or radical prostatectomy + pelvic LND (selected fit patients) |
| Very High / Locally Advanced | cT3b–T4, ISUP 5, or >4 cores ISUP 4 | Long-term ADT ± radiotherapy ± docetaxel; PSMA PET staging; MDT-guided |
| Metastatic | N1 or M1 any | ADT + docetaxel or abiraterone/enzalutamide (mHSPC). Bone protection (denosumab/zoledronic acid). |
Key Investigations
- mpMRI prostate (multi-parametric MRI) — performed BEFORE biopsy where possible. PI-RADS score 1–5. PI-RADS 4–5 requires biopsy.
- TRUS-guided biopsy — 12-core systematic ± MRI-fusion targeted cores for PI-RADS 3–5 lesions
- Bone scan — if PSA >20 ng/mL, Gleason ≥8, T3–T4, or bone symptoms. Detects osteoblastic metastases.
- PSMA PET-CT — superior sensitivity for nodal and distant metastases. Used for staging high-risk disease and detecting biochemical recurrence post-treatment.
- CT chest/abdomen/pelvis — lymph node staging for high-risk disease
- Germline testing — BRCA1/2, ATM, MMR genes — implications for PARP inhibitors (olaparib) and immunotherapy eligibility
PSA Monitoring Post-Treatment
Post-Radical Prostatectomy
PSA should be undetectable (<0.1 ng/mL) by 6–8 weeks. Biochemical recurrence (BCR): PSA ≥0.2 ng/mL on two consecutive measurements. Trigger for imaging and consideration of salvage radiotherapy.
Post-Radiotherapy (Phoenix Criteria)
PSA nadir + 2 ng/mL rise = biochemical failure after radical/salvage radiotherapy. PSA does not reach zero (residual prostate tissue). Nadir usually achieved 18–24 months post-RT.
Nursing Role in PSA Surveillance
- Ensure PSA taken at consistent intervals (3-monthly then 6-monthly then annually)
- Educate: rising PSA alone (without symptoms) is not an emergency but needs prompt reporting
- Document testosterone level alongside PSA in patients on ADT
- Assess for bone pain, new neurological symptoms at every visit
Androgen Deprivation Therapy (ADT) — Nursing Care
GnRH Agonists
Examples & Administration
Leuprolide (Lupron), Goserelin (Zoladex) — SC/IM depot injection every 1, 3, or 6 months. Goal: castrate testosterone (<50 ng/dL, ideally <20 ng/dL).
Testosterone Flare — First 1–2 weeks
GnRH agonists cause initial LH/FSH surge → transient testosterone rise → tumour stimulation risk. Danger in patients with spinal metastases (cord compression risk) or severe LUTS.
Prevention: Co-prescribe anti-androgen (bicalutamide 50mg OD) for 4 weeks starting 3–7 days BEFORE first GnRH agonist injection.
Hot Flushes Management
Affects up to 80% of patients. Options: venlafaxine 37.5–75mg OD, cyproterone acetate, medroxyprogesterone acetate, gabapentin. Non-pharmacological: fans, cool environment, layered clothing.
GnRH Antagonists & Anti-Androgens
GnRH Antagonist: Degarelix (Firmagon)
SC injection — immediate testosterone suppression. No testosterone flare — no anti-androgen cover needed. Suitable for spinal metastases or severe LUTS.
Side effects: injection site reactions (pain, erythema, induration at SC site) — common. Rotate sites. Apply cold pack.
Anti-Androgens: Bicalutamide
Competitive androgen receptor blocker. Used as monotherapy (for flare cover) or combined with GnRH agonist.
LFT monitoring: LFTs at baseline, 6 weeks, 3 months, then 6-monthly. Hepatotoxicity — if ALT >2× ULN, reduce or stop.
Novel Anti-Androgens (ARSI)
Enzalutamide (Xtandi), Apalutamide, Darolutamide, Abiraterone (Zytiga).Used in mHSPC and CRPC settings in addition to standard ADT.
Novel Anti-Androgen Monitoring — Key Side Effects
| Drug | Key Side Effect | Nursing Monitoring |
|---|---|---|
| Abiraterone (+ prednisolone 5–10mg) | Hypertension, fluid retention/oedema, hypokalaemia (mineralocorticoid excess) | BP monitoring (every visit), daily weight, potassium/LFTs monthly initially. Prednisolone compliance critical — adrenal crisis risk if stopped abruptly. |
| Enzalutamide | Fatigue (most common), falls, seizure risk (<1%), hypertension, cognitive changes | Falls assessment. Do not drive if seizure risk. BP monitoring. Assess fatigue impact on daily activities. |
| Apalutamide | Rash, fatigue, hypothyroidism, fracture risk | Skin assessment. TFTs 6-monthly. Falls/fracture risk. |
| Darolutamide | Fatigue, pain in extremities — lower CNS penetration (fewer cognitive effects) | Fatigue monitoring. Fewer drug interactions than enzalutamide. |
Long-Term ADT Side Effects & Prevention
| Side Effect | Prevention / Management |
|---|---|
| Osteoporosis | DEXA scan at baseline and 2-yearly. Calcium 1200mg + Vitamin D3 800–1000 IU daily. Bisphosphonate (zoledronic acid/alendronate) if T-score <−2.5. Weight-bearing exercise. |
| Cardiovascular risk | Lipid profile, HbA1c, BP at baseline and 6-monthly. Lifestyle: smoking cessation, exercise, diet. Metformin for new-onset diabetes. Cardiology referral if pre-existing CVD. |
| Sexual dysfunction / ED | PDE5 inhibitor (sildenafil) discussion. Penile rehabilitation. Psychosexual counselling referral. Cultural sensitivity in GCC. |
| Gynaecomastia | More common with bicalutamide monotherapy. Tamoxifen 20mg OD or breast irradiation prophylaxis. |
| Anaemia | Monitor FBC 3-monthly. Significant anaemia may limit chemotherapy eligibility. |
| Cognitive changes | Assess mood, memory. Refer neuropsychology if significant. Exercise programmes help. |
Castrate-Resistant Prostate Cancer (CRPC)
Definition
PSA progression or radiological progression despite castrate testosterone levels (<50 ng/dL). Confirm testosterone is truly castrate before diagnosing CRPC.
CRPC Treatment Pathway
- Continue ADT throughout all subsequent lines — testosterone should remain castrate
- mCRPC first-line: abiraterone or enzalutamide (if not used in mHSPC)
- Docetaxel 75mg/m² IV q3w — 10 cycles (if not used earlier)
- Cabazitaxel — second-line chemotherapy post-docetaxel
- Radium-223 (Xofigo) — bone-predominant mCRPC, no visceral mets, prolongs survival
- PARP inhibitors (olaparib, rucaparib) — BRCA1/2 or HRR gene mutation
- Pembrolizumab — MSI-high tumours
Radium-223 Nursing Points
IV injection monthly × 6. Radiation precautions: wear gloves when handling bodily fluids 1 week post-injection. Patient education on double flushing toilet. Bone marrow monitoring: FBC before each cycle.
Prostate Cancer in the GCC — Epidemiology & Context
Epidemiology in GCC vs Western Populations
- Lower incidence in GCC countries vs USA/Europe — approximately 5–8 per 100,000 vs 100+ per 100,000 in the USA
- Genetic/hereditary differences — lower prevalence of BRCA2 mutations in Gulf Arab populations vs African-Americans or Ashkenazi Jews
- Dietary factors — traditional Gulf diet historically lower in saturated fat and red meat; high lycopene from tomatoes in Levantine-influenced diets
- Rising incidence associated with Westernisation — adoption of high-fat diet, sedentary lifestyle, obesity
- Expatriate workforce in GCC (UAE, Qatar, Kuwait) — diverse ethnic backgrounds with varying risk profiles
- Underreporting likely — late presentation skews incidence data
PSA Screening in GCC
No National Screening Programme
As of current date, no GCC country has implemented a formal national population-based PSA screening programme. Saudi Vision 2030 health reforms and Qatar National Cancer Strategy acknowledge the need for early detection, but organised screening is not routine.
Late Presentation — Key Challenge
- Many GCC patients present with advanced (T3/T4, metastatic) disease
- Cultural reluctance to seek help for urinary / genital symptoms
- Perception that urinary symptoms are a normal part of ageing
- DRE avoidance — religious, cultural, privacy concerns
- Language barriers for non-Arabic speaking expatriate workers
Opportunistic Screening Approach
Nurses can promote PSA testing for men >50 years (or >40 years with family history) when presenting for any health reason — annual health checks, occupational health, pre-operative assessment.
Islamic & Cultural Considerations
DRE — Privacy, Dignity & Islamic Concerns
Same-Gender Provider Preference
In Islamic tradition (and across GCC cultures), intimate examinations are strongly preferred to be performed by same-gender healthcare providers. A female nurse should not perform or directly assist with DRE on a male patient unless there is no male provider available and medical necessity is immediate.
- Nursing action: Always ask patient preference before any intimate procedure
- Where possible, arrange male nurse or male physician for DRE preparation/assistance
- Ensure full privacy — closed door, curtains, minimum staff present
- Explain the medical necessity of the examination clearly before proceeding
- Allow patient to have a male family member present if preferred
- Document patient's consent and preferences in the nursing notes
- Some patients may initially refuse DRE — document refusal, re-educate at subsequent visit, consider PSA + mpMRI as alternative investigation pathway
Communication Tip
Frame DRE in the context of preventive health — "This examination can detect early problems that, if found early, can be treated successfully." Emphasise the nurse/doctor's professional role and the importance of modesty protocols.
Pelvic Floor Rehabilitation — Prayer Considerations
Post-Prostatectomy Urinary Incontinence
Pelvic floor muscle training (PFMT) is the first-line treatment for post-prostatectomy stress urinary incontinence. In GCC/Muslim men, concern about incontinence during prayer (Salah) is a major quality-of-life issue.
- Prayer involves repeated positions — standing, bowing (ruku), prostration (sujood), sitting — which all recruit pelvic floor muscles
- These prayer positions can be used as functional pelvic floor exercises — contraction with each movement
- Educate patient to perform pelvic floor contractions (Kegel exercises) during transition between prayer positions
- Advise voiding immediately before prayer to reduce leakage risk
- Wudu (ritual washing) concern: incontinence may invalidate wudu — reassure patient that incontinence (due to medical cause) is recognised in Islamic jurisprudence (fiqh) as exemption
- Refer to urology nurse specialist or continence advisor for formal PFMT programme
- Penile clamp or absorbent pads as temporary measure while awaiting PFMT effect (typically 3–6 months)
Erectile Dysfunction Post-Treatment — Cultural Sensitivity
Prevalence & Reluctance to Discuss
Erectile dysfunction (ED) occurs in 60–90% following radical prostatectomy and up to 50% after radiotherapy. In GCC cultural contexts, sexual health discussion may be taboo. Men may feel shame or embarrassment, and may not voluntarily raise concerns.
- Normalise the discussion — routinely ask about sexual function as part of quality-of-life assessment at every oncology/urology follow-up
- Use validated tools sensitively: IIEF (International Index of Erectile Function) can be self-administered for privacy
- Nerve-sparing prostatectomy — counsel about possibility pre-operatively, document patient's priorities regarding continence vs potency
- Penile rehabilitation — early PDE5 inhibitor use (sildenafil 25–50mg nightly or on-demand) for nerve recovery post-surgery
- Vacuum erection devices, intracavernosal injections as alternatives
- Psychosexual counselling — involve partner where culturally appropriate and consented
- ADT-related ED — reversible in many cases after ADT cessation; however recovery takes 12–24 months
Arabic Language Education & Stigma Reduction
Overcoming Stigma of Prostate Cancer
Prostate cancer carries additional stigma in GCC communities compared to Western settings — it involves sexual organs, treatment affects masculinity and fertility, and discussing symptoms requires disclosure of intimate health concerns.
- Provide patient education materials in Arabic — avoid medical jargon; use plain language
- Key Arabic terms to know: البروستاتا (al-burūstāta) — prostate; سرطان البروستاتا (saratān al-burūstāta) — prostate cancer; مستضد البروستاتا النوعي (PSA) — PSA test
- Involve family (with patient consent) — in GCC culture, family is central to health decisions; educate male family members who may accompany patient
- Use community health programmes during Ramadan health camps, national health days
- Work with imams and religious leaders to promote awareness — religious community trust is high
- Peer support groups — men who have been successfully treated can be powerful advocates
- Social media campaigns (Twitter/X, Instagram) in Arabic — major channels for health information in GCC
Key Nurse Advocacy Role
The nurse is often the most accessible healthcare professional. Use every encounter with male patients >50 years as an opportunity to discuss prostate health, normalise PSA testing, and challenge stigma through respectful, culturally-informed education.